News und Analysen
Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS)
DGAP-News: Vita 34 records moderate upward trend in the second quarter
MD Medical Group Investments Plc: Results of the Extraordinary General Meeting of shareholders
DGAP-Adhoc: Vita 34 lowers sales and earnings guidance due to IFRS 15 effect and accelerated restructuring measures
DGAP-News: M1 Kliniken AG announces financials for H1-2022: positive business development despite cooling of general consumer climate
DGAP-News: Eckert & Ziegler with Successful First Half of 2022
STAAR Surgical Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the
MD Medical Group Investments Plc: MD Medical Group announcement of the extraordinary general meeting
H1 2022: Temporary supply constraints slow down strong demand
Inogen Announces Second Quarter 2022 Financial Results
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30
Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pKa)
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it has entered a new collaboration
NanoString to Webcast Presentations from Two Upcoming Healthcare Conferences
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast
DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q2 2022
DGAP-News: MediClin AG: Consolidated sales for the first half of 2022 up 10% on the previous pandemic figure – no change in forecast
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
Simulations Plus Presented New Scientific Developments at PAGE 2022
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the presentation of five scientific
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit International Organization for Childhood Cancer
Simulations Plus (Nasdaq: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation to St. Jude Children’s
DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development
STAAR Surgical to Report Second Quarter Results on August 10, 2022
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release
DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
Simulations Plus Realizes Early Success with its Concierge Program
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, recently invested in the creation of their
Simulations Plus Reports Third Quarter Fiscal 2022 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its third
DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
DGAP-Adhoc: Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm EUR